Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients

BACKGROUND: Most non‐small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase‐tyrosine kinase inhibitor (ALK‐TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK‐TKI therapies; however, little clinical data ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Haratake, Naoki, Seto, Takashi, Takamori, Shinkichi, Toyozawa, Ryo, Nosaki, Kaname, Miura, Naoko, Ohba, Taro, Toyokawa, Gouji, Taguchi, Kenichi, Yamaguchi, Masafumi, Shimokawa, Mototsugu, Takenoyama, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718030/
https://www.ncbi.nlm.nih.gov/pubmed/31338990
http://dx.doi.org/10.1111/1759-7714.13143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718030/
https://www.ncbi.nlm.nih.gov/pubmed/31338990
http://dx.doi.org/10.1111/1759-7714.13143

Ejemplares similares